ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII) said today that its President and CEO, David Martin, has recently been diagnosed with cancer and is undergoing treatment. Martin is feeling well and will continue to perform his duties as CEO, though some activities, such as travel, may be limited.
Scott Ward, Chairman of CSI’s Board, said, “Dave is an outstanding leader and has the full support of the Board. We wish him a rapid recovery. While he will continue to serve as CEO, Dave has also developed a talented management team that we are confident can lead the company as needed during his treatment and recovery.”
Earlier today, Martin sent a letter to CSI employees sharing his diagnosis. A copy of that letter can be found here: http://investors.csi360.com/Investors/Investor-Resources/Letter.
About Cardiovascular Systems, Inc.
Cardiovascular Systems,
Inc., based in St. Paul, Minn., is a medical device company focused on
developing and commercializing innovative solutions for treating
vascular and coronary disease. The company’s Orbital Atherectomy Systems
treat calcified and fibrotic plaque in arterial vessels throughout the
leg and heart in a few minutes of treatment time, and address many of
the limitations associated with existing surgical, catheter and
pharmacological treatment alternatives. The U.S. FDA granted 510(k)
clearance for the use of the Diamondback Orbital Atherectomy System in
peripheral arteries in August 2007. In October 2013, the company
received FDA approval for the use of the Diamondback Orbital Atherectomy
System in coronary arteries. To date, nearly 210,000 of CSI’s devices
have been sold to leading institutions across the United States. For
more information, visit the company’s website at www.csi360.com.